QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Aurinia Pharmaceuticals Inc. (AUPH)

Healthcare

No action
Fundamental
4
Sentiment
3
Technical
2

Do Nothing: technicalScore 2 (weak, bounce-only tape - price 15.87 below SMA20 16.71, SMA50 16.48, EMA9 16.42 and EMA21 16.55 with MACD -0.06 below signal 0.05 and histogram -0.12) is under the >= 3 entry requirement; the pullback/oversold limit was also rejected as countertrend (price < SMA50 with MACD < 0), and the breakout stop candidate at 16.69 above the settled 2026-11-10 high prices at R/R 1.01 with no momentum confirmation, below the 1.5 hurdle - no entry qualifies.

Analysis as of 2026-11-11· more than 2 trading days ago

Company overview

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for diseases with inadequate current treatments. Its main product, LUPKYNIS, is approved for treating active lupus nephritis in adults. The company collaborates with Otsuka Pharmaceutical and is headquartered in Victoria, Canada.

Fundamental

good
Fundamental4
Solid fundamentals

Aurinia shows strong profitability and cash generation, but faces single-product and litigation risks.

Profitable, net-cash commercial biotech: LUPKYNIS is driving high-teens revenue growth, 90% gross margins and $131.5M of nine-month operating cash flow, funding buybacks while the cash pile grows to $486.9M; FY2025 earnings were flattered by a $173M one-time tax benefit, and single-product, sole-supplier, remaining ANDA patent litigation and a near-52-week-high valuation temper the picture.

Sentiment

fair
Sentiment3
Mixed / forming

Sentiment is mixed with a beat-and-raise catalyst, but lacks a clear forward driver and has conflicting narratives.

A mixed, forming setup: the Q3 2026 beat-and-raise (2026-10-30, announced) plus a post-print RBC price-target increase are market-rewarded bullish catalysts, but the sentiment delta is indeterminate (the 30-90d baseline produced only two scored items) and retail is unmeasured (Reddit 403), with a genuinely two-sided post-print narrative — moderate red-flag cap applied for conflicting catalyst signals.

Technical

weak
Technical2
Weak technicals

Aurinia's technicals indicate a weak, non-trending tape with no actionable long setup.

AUPH scores 2/5 on the chart: the two-week slide from 17.36 (2026-10-28) to 15.78 leaves price 5.0% under the SMA20 (16.71), 3.7% under the SMA50 (16.48) and below every short-horizon average (EMA9 16.42, EMA21 16.55, WMA9 16.35, WMA21 16.62, DEMA14 16.37, TEMA14 16.17), with only the SMA200 (15.71) still beneath it. Momentum is negative - the MACD line has crossed under its signal (-0.06 vs 0.05) with the histogram expanding to -0.12, RSI14 is 41.05, and ADX14 at 16.93 is fading from 25+, so this is a weak, non-trending tape rather than a base. Williams %R -99.45 on the latest bar and an ATR14 equal to 3.34% of price mark a stretched, bounce-only condition. Liquidity ($14.35M/day 20-day average, ~$12.16M/day over the last three sessions) and volatility (3.34% ATR) are adequate; what fails is confirmation and score. The pullback/oversold LIMIT path is countertrend by the SMA50/MACD test (price 15.87 < sma50 16.48 and macdLine -0.06 < 0), and the only breakout STOP candidate (16.69, above the settled 2026-11-10 high 16.68) prices at R/R 1.01 against a structural stop at 15.64 with no momentum confirmation. Nothing qualifies at the >= 3 score and >= 1.5 R/R hurdles, so the verdict is Do Nothing.

You’re looking at 2026-11-11 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.